$RARE

Ultragenyx (RARE) shares dropped 44.7% premarket after its Phase 3 Aspire study for apazunersen in Angelman syndrome missed primary and key secondary endpoints. Analysts downgraded the stock, with price targets lowered significantly. Shares fell below their 52-week low. According to the company, no meaningful differences were found between treatment and placebo groups.

Ultragenyx Pharmaceutical Inc. (RARE) stock rose 3.57% after positive coverage of its rare disease pipeline. However, it later plunged 45% due to the failure of the GTX-102 Phase 3 trial. The company reported $214M in revenue and an 87.8% gross margin but posted a net loss of $92M. Analysts have mixed views, with some cutting price targets while others maintain an Overweight rating. The stock is highly volatile, trading at $15.35 after the drop.

Ultragenyx Pharmaceutical Inc. (RARE) stock rose 3.3% after positive clinical trial results for Genglycos, but later crashed 44.6% due to the failure of GTX-102. The company reported $673M in revenue, but deep losses and high cash burn raise concerns. Analysts remain neutral, citing high risk and potential upside.

Goldman Sachs maintained a Neutral rating for Ultragenyx Pharmaceutical (RARE) but lowered its price target to $19.00 from $28.00, citing concerns about growth and profitability. The stock is currently trading at $15.76, with a GF Value™ of $45.26, suggesting it is undervalued by 65.2%. Ultragenyx has a GF Score™ of 68/100, indicating moderate overall performance with strengths in growth but weaknesses in profitability and financial strength.

U.S. stock futures rose slightly ahead of the August Nonfarm Payrolls report, with Nasdaq futures up 0.4%. Key companies in focus include TSLA, LULU, ORCL, NVDA, and PLTR. Economists expect 53,000 jobs added in August, with the unemployment rate forecast at 4.1%. Fed Governor Waller suggested a rate hike could be appropriate if inflation doesn't moderate. NVDA shares rose after a $12.93B deal, LULU shares fell 17% after missing estimates, and ORCL shares rose 1% after a network equipment agreeme

Tyson Foods fell 7% after cutting fiscal 2026 guidance. Meta rose 3% on AI model launch. Dell gained 5% post-earnings. Crypto-related stocks climbed with bitcoin. Robinhood jumped 15% on Deutsche Bank's report. Ciena dropped 9% despite beating estimates. Tesla advanced 6% ahead of Cybercab event. Snowflake surged 22% on strong earnings. HPE slipped 4% with lower-than-expected growth forecast. Broadcom lost 3% on weak revenue outlook. Campbell's fell 9% on lagging guidance. Ultragenyx plunged 44%

Ultragenyx Pharmaceuticals (RARE) shares fell 47% after its experimental Angelman syndrome treatment, apazunersen, failed in Phase 3 trials. The drug did not improve cognition or meet a composite response score, according to the company.

Ultragenyx's gene therapy GTX-102 for Angelman syndrome failed in Phase 3 trials, showing no benefit over placebo. The company plans significant expense reductions following the setback.

Ultragenyx Pharmaceutical (RARE) was downgraded by Evercore ISI Group from 'Outperform' to 'In-Line' with a new price target of $16, down from $34. The company's GF Value is $45.29, suggesting a 41.4% undervaluation. RARE has a GF Score of 68/100, indicating moderate performance with strengths in growth but weaknesses in profitability and financial strength. Insider sell activity totaled $416,870 over the last three months.

Analysts updated price targets for several companies. HC Wainwright cut Ultragenyx's (RARE) target to $25. Needham raised UiPath's (PATH) target to $22. BTIG increased Netskope's (NTSK) target to $18 and Snowflake's (SNOW) to $424. Needham also raised Magnite's (MGNI) target to $30. Cantor Fitzgerald boosted Broadcom's (AVGO) target to $600. Baird increased CrowdStrike's (CRWD) target to $235. Rothschild & Co raised Moderna's (MRNA) target to $81 but downgraded it. B of A cut Sonoco's (SON) targ